Combined Cancer Therapy Increased Salivary Flow
A 2023 study found that combining photobiomodulation with pilocarpine improved saliva production in cancer patients.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Should patients trust medical study findings that are based on very small participant groups?
Researchers evaluated a combined regimen of photobiomodulation therapy and pilocarpine hydrochloride in 24 head and neck cancer patients. Registered on August 21, 2023, the study indicated improved stimulated salivary flow for patients in the combined treatment group compared to other methods.
Why it matters
Hyposalivation is a frequent and debilitating complication for patients undergoing radiochemotherapy for head and neck cancer. Improving salivary function is critical for maintaining oral health and quality of life during and after aggressive oncological treatments.
In a study of 24 participants, the combined treatment group showed a mean stimulated salivary flow increase of 0.33 mL/min over photobiomodulation between the end of radiochemotherapy and the 3-month follow-up.
The players
ISRCTN
The International Standard Randomised Controlled Trial Number registry provides a unique identifier for clinical trials to ensure transparency.
The details
The study randomized patients into pilocarpine, photobiomodulation, or combined treatment groups to assess salivary flow rates, pH, and electrolyte concentrations. While the primary endpoint showed no overall significant difference, the combined group demonstrated notable improvements at the 3-month follow-up mark.
Timeline
August 21, 2023: The clinical trial was registered in the ISRCTN registry.
Baseline: Initial salivary assessments were performed.
End of RCT: Secondary salivary assessments were performed.
3-month follow-up: Final salivary assessments were performed.
Health Landscape
This study contributes to the body of evidence tracked by the ISRCTN clinical trial registry, which aims to standardize and validate supportive care protocols for cancer survivors. The results highlight the potential for non-pharmacological adjuncts to traditional oncology treatments.
Patients experiencing chronic dry mouth due to radiation therapy may eventually benefit from these combined therapies to alleviate discomfort. However, individuals should consult with their oncology care team before incorporating new treatments into their recovery routines.
The takeaway
Targeting side effects like hyposalivation is an essential component of comprehensive cancer care. Continued research into multimodal therapies may lead to better long-term management of treatment-related complications.
Further reading
For more information on ongoing clinical research, visit the Cancer section.
More information
Read the complete ISRCTN clinical trial registration to understand the full methodology and findings.
Source note: This article includes information reported by Nature.
Live Poll
Should patients trust medical study findings that are based on very small participant groups?
